Last updated: 18 July 2019 at 5:06pm EST

Ronald D Boyd Net Worth




The estimated Net Worth of Ronald D Boyd is at least $399 Thousand dollars as of 15 December 2017. Ronald Boyd owns over 25,000 units of Rockwell Medical Inc stock worth over $275,930 and over the last 21 years Ronald sold RMTI stock worth over $123,200.

Ronald Boyd RMTI stock SEC Form 4 insiders trading

Ronald has made over 11 trades of the Rockwell Medical Inc stock since 2009, according to the Form 4 filled with the SEC. Most recently Ronald exercised 25,000 units of RMTI stock worth $162,500 on 15 December 2017.

The largest trade Ronald's ever made was exercising 25,000 units of Rockwell Medical Inc stock on 15 December 2017 worth over $162,500. On average, Ronald trades about 4,645 units every 100 days since 2003. As of 15 December 2017 Ronald still owns at least 67,300 units of Rockwell Medical Inc stock.

You can see the complete history of Ronald Boyd stock trades at the bottom of the page.



What's Ronald Boyd's mailing address?

Ronald's mailing address filed with the SEC is 1912 WEST HAMPTON POINT DRIVE, , STATESBORO, GA, 30458.

Insiders trading at Rockwell Medical Inc

Over the last 21 years, insiders at Rockwell Medical Inc have traded over $3,082,721 worth of Rockwell Medical Inc stock and bought 689,891 units worth $3,959,861 . The most active insiders traders include Robert L Chioini, David S.Rbi Private Investm..., and Thomas E Klema. On average, Rockwell Medical Inc executives and independent directors trade stock every 45 days with the average trade being worth of $170,433. The most recent stock trade was executed by David S.Rbi Private Investm... on 21 December 2020, trading 42,450 units of RMTI stock currently worth $43,724.



What does Rockwell Medical Inc do?

rockwell medical is a fully-integrated biopharmaceutical company targeting end-stage renal disease (esrd) and chronic kidney disease (ckd) with innovative products and services for the treatment of iron replacement, secondary hyperparathyroidism and hemodialysis. rockwell’s new innovative therapy triferic is the only fda approved drug indicated to replace iron and maintain hemoglobin in hemodialysis patients suffering from anemia. via dialysate during each dialysis treatment, triferic replaces the 5-7 mg iron loss that occurs in all patients, maintaining their iron balance. unlike iv iron products, triferic binds iron immediately and completely to transferrin (carrier of iron in the body) upon entering the blood and is then transported directly to the bone marrow to be incorporated into hemoglobin, with no increase in ferritin (stored iron and inflammation) and no anaphylaxis, addressing a significant unmet need in overcoming functional iron deficiency (fid) in esrd patients. visit www



What does Rockwell Medical Inc's logo look like?

Rockwell Medical Inc logo

Complete history of Ronald Boyd stock trades at Rockwell Medical Inc

Date
#
Company
Insider
Trans.
Transaction
Shares Price per share Total value Shares after Source
15 Dec 2017 Ronald D Boyd
Director
Option 25,000 $6.50 $162,500
15 Dec 2017
67,300
4 Dec 2015 Ronald D Boyd
Director
Option 12,500 $4.55 $56,875
4 Dec 2015
45,000
18 Dec 2014 Ronald D Boyd
Director
Option 12,500 $2.79 $34,875
18 Dec 2014
12,500
7 Jan 2014 Ronald D Boyd
Director
Option 5,000 $4.05 $20,250
7 Jan 2014
5,000
12 Sep 2013 Ronald D Boyd
Director
Option 12,500 $3.06 $38,250
12 Sep 2013
25,000
17 Jun 2013 Ronald D Boyd
Director
Option 12,500 $1.81 $22,625
17 Jun 2013
12,500
18 Mar 2011 Ronald D Boyd
Director
Sale 4,000 $8.80 $35,200
18 Mar 2011
0
16 Mar 2011 Ronald D Boyd
Director
Sale 10,000 $8.80 $88,000
16 Mar 2011
4,000
14 Mar 2011 Ronald D Boyd
Director
Option 20,000 $0.67 $13,400
14 Mar 2011
20,000
23 Jun 2009 Ronald D Boyd
Director
Option 10,000 $0.55 $5,500
23 Jun 2009
10,000
19 Jun 2009 Ronald D Boyd
Director
Option 20,000 $1.88 $37,600
19 Jun 2009
20,000


Rockwell Medical Inc executives and stock owners

Rockwell Medical Inc executives and other stock owners filed with the SEC include: